Jump to content
  • Rosacea Research

    microscope.jpgrrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    Rosacea Research

    Rosaceans can make a difference in rosacea research by joining the RRDi as a corporate member. Please join and VOLUNTEER

    The RRDi could engage in some novel rosacea research. You can become involved with this volunteer movement of rosaceans making a difference in the direction of rosacea research. Never underestimate the power of rosaceans volunteering. For example, you could volunteer as a grant writer (if you have no experience you could learn how). If you are a professional grant writer, or would like to learn how to write grants for rosacea research, please click here.

    Joel T. Bamford, M.D., wrote an article in the Journal of the RRDi entitled, "Is it possible for rosaceans to do research?" The answer to that question is joining our cause and making this possible. The RRDi is in the forefront of the medical digital revolution which you can be a part of. For more information click here.

    "However, as another important outcome, their analyses also highlighted the need for better-quality studies evaluating treatments for rosacea....The reviewers also found there were no randomized, controlled trials evaluating other treatments commonly used for rosacea, including doxycycline, minocycline, isotretinoin, laser therapy, erythromycin, dapsone and topical tretinoin." [1]

    According to Michael Detmar, M.D., in 2003, only one paper was published for every 144,000 rosacea patients in the United States, compared to a 1-to-11 ratio for melanoma and 1 to 4,900 for psoriasis. [Source]

    sci_w_tube.jpg

    RRDi Education Grants

    The RRDi has funded educational grants sponsored by Galderma. For more information click here.

    Volunteer

    If you want to become involved as a volunteer you can begin to educate yourself with the following subjects on rosacea research:

    Rosacea Research in Perspective of Idiopathic Diseases

    Rosacea Research in Perspective of Funding

    Rosacea Research Forum

    Rosacea RRDi Research Articles

    Call For Papers - Journal of the RRDi. Volume 2, No. 1

    Rosaceans Funding Rosacea Research
    Could 10K members of the RRDi get together and each donated one dollar and fund a double blind, placebo controlled, peer reviewed clinical study research paper on rosacea? Only if you become involved. That is what volunteering is all about. Donate.

    End Notes

    [1] Rosacea Treatment Studies Scrutinized by Reviewers
    Better-quality assessments essential to evaluate treatments, analysis shows
    Dermatology Times, Publish date: Feb 1, 2005 By: Cheryl Guttman



  • Posts

    • Antibiotics (Basel). 2024 Mar 17;13(3):270. doi: 10.3390/antibiotics13030270. ABSTRACT Clindamycin is a highly effective antibiotic of the lincosamide class. It has been widely used for decades to treat a range of skin and soft tissue infections in dermatology and medicine. Clindamycin is commonly prescribed for acne vulgaris, with current practice standards utilizing fixed-combination topicals containing clindamycin that prevent Cutibacterium acnes growth and reduce inflammation associated with acne lesion formation. Certain clinical presentations of folliculitis, rosacea, staphylococcal infections, and hidradenitis suppurativa are also responsive to clindamycin, demonstrating its suitability and versatility as a treatment option. This review describes the use of clindamycin in dermatological practice, the mechanism of protein synthesis inhibition by clindamycin at the level of the bacterial ribosome, and clindamycin's anti-inflammatory properties with a focus on its ability to ameliorate inflammation in acne. A comparison of the dermatologic indications for similarly utilized antibiotics, like the tetracycline class antibiotics, is also presented. Finally, this review addresses both the trends and mechanisms for clindamycin and antibiotic resistance, as well as the current clinical evidence in support of the continued, targeted use of clindamycin in dermatology. PMID:38534705 | DOI:10.3390/antibiotics13030270 {url} = URL to article
    • Rev Soc Bras Med Trop. 2024 Mar 25;57:e008042024. doi: 10.1590/0037-8682-0605-2023. eCollection 2024. ABSTRACT Cutaneous involvement in paracoccidioidomycosis (PCM) can exhibit a highly polymorphic spectrum. The infiltrative pattern corresponds to up to 26.6% of observed skin lesions, including sarcoid-like plaques, a rare presentation of cutaneous lesions in PCM. This clinical expression is almost exclusively cutaneous, and its histology reveals a tuberculoid granuloma with a scarcity of fungi, leading to misdiagnosis as other granulomatous diseases. Here, we report a rare form of chronic multifocal paracoccidioidomycosis manifesting as sarcoid-like skin lesions misdiagnosed as granulomatous rosacea in a patient with severe systemic disease. PMID:38537002 | DOI:10.1590/0037-8682-0605-2023 {url} = URL to article
    • Get free samples of Roversol for rosacea while supplies last. 
    • Otol Neurotol Open. 2023 Nov 22;3(4):e043. doi: 10.1097/ONO.0000000000000043. eCollection 2023 Dec. ABSTRACT BACKGROUND: Pulsatile tinnitus (PT) is increasingly recognized as a cardinal symptom of idiopathic intracranial hypertension (IIH). However, clinicians should remain aware of other causes of nonidiopathic or secondary intracranial hypertension manifesting as PT. We present 2 patients with isolated PT (without accompanying headache, blurred vision, and papilledema) thought to be secondary to tetracycline-induced intracranial hypertension. To our knowledge, these are the first cases of PT as the presenting symptom of this condition. CASES: A 41-year-old female (body mass index [BMI] 29 kg/m2) with ocular rosacea was initially treated with minocycline. Shortly after transitioning to oral doxycycline and erythromycin eye ointment, she noted left-sided PT. Her PT resolved after discontinuing doxycycline. In a second case, a 39-year-old female (BMI 19 kg/m2) with acne presented with a three-year history of left-sided PT while on long-term oral doxycycline for many years. She denied visual or auditory changes and atypical headaches. MRI findings were concerning for intracranial hypertension. Three months later, the patient was seen by neuro-ophthalmology, with findings suggesting prior papilledema. The patient reported PT improvement after discontinuing doxycycline. CONCLUSIONS: This case series highlights 2 cases of isolated PT as the sole symptom of intracranial hypertension that resolved with tetracycline cessation. The presentation and unexpected improvement following tetracycline discontinuation are atypical compared with previous reports of tetracycline-induced intracranial hypertension. Clinicians should maintain a high index of suspicion for all types of intracranial hypertension (idiopathic and secondary), even in patients with a lower BMI. Current and prior medications should be reviewed when considering the etiology of intracranial hypertension. PMID:38516546 | PMC:PMC10950181 | DOI:10.1097/ONO.0000000000000043 {url} = URL to article
    • Ocul Immunol Inflamm. 2024 Mar 21:1-8. doi: 10.1080/09273948.2024.2328791. Online ahead of print. ABSTRACT PURPOSE: The objective of this study was to illustrate the changes in ocular findings, meibography, and tear break-up time (TBUT) values in pediatric patients with ocular rosacea following a standardized treatment. METHODS: The study included consecutive patients diagnosed with ocular rosacea, referred to a tertiary hospital between 2021 and 2023. Each patient underwent biomicroscopic examinations, non-invasive TBUT assessments, corneal fluorescein staining (evaluated using the Oxford scoring system), and meibography. The standard treatment protocol involved warm compresses, eyelid hygiene, preservative-free sodium hyaluronate eye drops (administered four times daily), topical azithromycin 1.5% (twice daily for 3 days), topical steroids (loteprednol 0.5%, four times daily for 2 weeks), and either doxycycline 100 mg/day for 14 days or oral suspension of azithromycin 10 mg/kg for 3 days followed by an additional three-day course of treatment administered 10 days later (for patients above and below 14 years of age, respectively). RESULTS: The study included 18 patients, with 10 (55.5%) being female and 8 (44.4%) being male, with a mean age of 9.7 ± 4.5 years (range: 3-18). Four patients displayed cutaneous involvement. The treatments resulted in significant improvements in the Oxford scores, reduction in corneal neovascularization, and increased TBUT (p < 0.001, p = 0.016, p < 0.001, respectively). Meibomian gland loss area also significantly improved post-treatment (27.4 ± 6.7% vs 39.2 ± 13.4%, p = 0.001). CONCLUSION: This study demonstrated that pediatric ocular rosacea patients may exhibit improved meibomian gland function, regression of corneal neovascularization, and enhanced tear film parameters following a standardized treatment protocol that includes both topical and systemic approaches. PMID:38512290 | DOI:10.1080/09273948.2024.2328791 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use